Incidence of Occluded Culprit Arteries and Impact of Coronary Collaterals on Outcome in Patients With NSTEMI

Substudy of the Leipzig Immediate Versus Early and Late Percutaneous Coronary Intervention Trial in NSTEMI - LIPSIA-NSTEMI TRIAL

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01159366

Enrollment

602

Registered

2010-07-09

Start date

2006-07-31

Completion date

2010-01-31

Last updated

2010-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSTEMI

Keywords

myocardial infarction, coronary occlusion, myocardial revascularization, collaterals, prognosis

Brief summary

It is assumed that patients with non-ST-elevation myocardial infarctions (NSTEMI) showing an infero- or posterolateral occluded culprit artery (OCA) during diagnostic angiography frequently elude standard 12-lead electrocardiogram diagnosis. In addition, coronary collaterals may have beneficial effects in patients with OCA.

Detailed description

We examined consecutive NSTEMI patients within 48 h of symptom onset. All patients underwent early invasive angiography plus optimal medical therapy. We compared baseline characteristics, procedural findings including analysis of TIMI-flow and collaterals using the Rentrop-classification, 30-day and 6-months major adverse cardiovascular events (MACE) in patients with and without totally OCA.

Interventions

PROCEDUREpercutaneous coronary intervention

early timing

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* age between 18 and 90 years, * onset of angina pectoris at rest \<24 h or crescendo angina in recent weeks with symptoms under minimal exertion or at rest lasting \<24 h, * elevated troponin T ≥0.03 µg/L and * written informed consent.

Exclusion criteria

* persistent angina, * ST-segment elevation myocardial infarction (STEMI), * hemodynamic instability including cardiogenic shock, * oral anticoagulation therapy, * contraindications for glycoprotein IIb/IIIa inhibitors, * other disease with life expectancy \<6 months, * known coagulopathy, * pregnancy, * other suspected causes of troponin elevation as myocarditis, secondary to hypertensive crisis, or after cardiac decompensation, * no ability to consent, and * participation in another study.

Design outcomes

Primary

Measure	Time frame	Description
MACE	6 months	composite of death, reinfarction and readmission for unstable angina within 6 months after inclusion

Secondary

Measure	Time frame	Description
CK and CK-MB	48 hours	Venous blood samples were taken at admission (baseline), and every 6 h subsequently for a period of 48 h.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026